Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antineoplastons A10 and AS2-1 in Advanced Breast Cancer
NCT00003455Phase 2
Key facts
- Status
- Withdrawn
- Countries
- 1
- Sponsor
- Burzynski Research Institute
- Modality
- Peptides, Small Molecules
- Conditions
- breast cancer
01
Overview
Phase 2, open-label, single-arm trial of antineoplaston A10 and antineoplaston AS2-1 in breast cancer, sponsored by Burzynski Research Institute. Primary endpoint: Objective Tumor Response. Status: withdrawn.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
Treatment Arm
Patients receive oral antineoplaston A10 and antineoplaston AS2-1
03
Who it enrols
Women with histologically confirmed stage IV breast cancer who have failed prior standard therapy and have measurable disease.
04
Endpoints
Primary
Objective Tumor Response
Secondary
Adverse Effects and Tolerance
Survival
Beyond the preview
Go deeper on NCT00003455.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003455.